Currently, PD-L1 expression and tumor mutation load (TML) or tumor mutation burden (TMB) are the two main independent biological traits of NSCLC, having been validated for their predictive value in terms of immunotherapy [7]. The gene discussed is CD274; the disease is neoplasm.